Positive clinical trial results often lead to increased investor confidence in a company's pipeline and potential for future revenue growth, especially for treatments in underserved markets. This announcement could therefore positively influence Eli Lilly's stock price in the short term as it highlights the effectiveness of Lebrikizumab, potentially expanding its market reach and improving its competitive position in dermatology.